Condition: Malignant Female Reproductive System Neoplasm · Recurrent Cervical Carcinoma · Recurrent Endometrial Carcinoma · Sponsor: M.D. Anderson Cancer Center
This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.
This description comes directly from the study's public registry record.
Lilie Lin · 713-563-2300 · lllin@mdanderson.org
Always discuss trial participation with your own doctor first.
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore, Maryland, United States | Recruiting |
| M D Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03968406